
Sign up to save your podcasts
Or


He highlights Teva's improved financial position, its commercial prowess, and the pipeline assets to watch, including a TL1A that biotech investors have been watching closely.
By BiotechTV4.3
66 ratings
He highlights Teva's improved financial position, its commercial prowess, and the pipeline assets to watch, including a TL1A that biotech investors have been watching closely.

3,222 Listeners

1,910 Listeners

124 Listeners

324 Listeners

61 Listeners

9,957 Listeners

86 Listeners

34 Listeners

353 Listeners

19 Listeners

60 Listeners

512 Listeners

41 Listeners

0 Listeners

4 Listeners

2 Listeners

6 Listeners

48 Listeners